PCF 2022

Predicting Treatment Response in Prostate Cancer: The Power of Spatial Proteomic Approaches - Christina Curtis

Understanding the Potential and Challenges of Sipuleucel-T and Radium-223 in the Management of Metastatic Castration-Resistant Prostate Cancer - Sumit Subudhi

Dissecting the Dynamics of the Tumor Microenvironment: Nutrient Availability and Treatment Outcomes - Asmaa El-Kenawi

DLL3 Targeting Bispecifics: A New Hope for Tough-to-Treat Prostate Cancer Patients - Rahul Aggarwal

The Benefit to Radium-223 Added to Cabozantinib for Patients With Renal Cell Carcinoma With Bone Metastasis, RadiCaL - Rana McKay

A Historical Perspective on Radioligand Therapy and Novel Treatment Modalities in the Management of mCRPC - Neil H. Bander

Unveiling the Clinical Potential of ctDNA: Implications for Prostate Cancer Management - Neeraj Agarwal

The Support and Momentum of the Prostate Cancer Foundation on Prostate Cancer Research and Treatment - Edwin Posadas

Immune System Biology of Androgen and AR Functions in T cells in Prostate Cancer - Amy Moran

The Impact of Molecular and Genomic Factors on Prostate Cancer Disease Etiology and Health Disparities and The State of Science on Diet and Lifestyle - Lorelei Mucci

Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg

Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor

From Active Surveillance to Novel Biomarkers: A Seamless Approach to Prostate Cancer Research - Jeff Tosoian

From Blood to Diagnosis: the Role of ctDNA in Prostate Cancer Treatment - Alexander Wyatt

Targeting Tumor Marker B7-H3 with Engineered Natural Killer Cells - Nicholas Zorko

Convergent Therapeutics, Inc. Next Generation Radiopharmaceutical Therapies for Prostate - Philip Kantoff

Engineered Cell Therapies for Metastatic Castrate-Resistant Prostate Cancer - Saul Priceman

Heterogeneity in Multifocal Prostate Cancer - Simpa Salami

Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial - Alan Bryce

Biological Difference Based on Race: Disparities Throughout the Spectrum of Prostate Cancer - Kosj Yamoah

Disparities in Prostate Cancer: Barriers to Access to Clinical Trials - Elisabeth Heath

Bipolar Androgen Therapy in the Management of Prostate Cancer - Samuel Denmeade

Developing a Blood-Based Biomarker Platform to Predict Treatment Outcomes in Prostate Cancer Patients - Martin Sjöström

Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis

Using Liquid Biopsies in Clinical Practice to Inform Decision Making for Prostate Cancer Care - Joshua Lang

Veterans Affair Care Program, Prostate Cancer Biorepository - Isla P. Garraway

Exploring the Potential of Lutetium PSMA in High-Risk Localized Prostate Cancer: The LuTectomy Trial - Renu Eapen

Addressing Prostate Cancer Health Disparities - Leanne Woods-Burnham

Contact-02: A Phase III Trial Shaping the Future of Metastatic Prostate Cancer Care - Neeraj Agarwal

Longitudinal Patient Sampling and Immune Profiling in Oligometastatic Prostate Cancer - Sophia Kamran

Scaling Up Point-of-Care Genetic Testing in the VA: A Nurse-Led Initiative - Kara Maxwell

Exploring the PROSPER Study: A Neoadjuvant Approach to Kidney Cancer - Mohamad Allaf

The AFT-19 Study: A Comprehensive Look at High-Risk Prostate Cancer Treatment - Rahul Aggarwal

Exploring the Nuances of the PRONOUNCE Trial - Celestia Higano

Navigating the Challenges of Somatic Mutation Testing in Prostate Cancer - Joaquin Mateo

A Journey Through Prostate Cancer Research: Perspective on the Prostate Cancer Foundation's Impact - Philip Kantoff